<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426592</url>
  </required_header>
  <id_info>
    <org_study_id>2016.362</org_study_id>
    <nct_id>NCT03426592</nct_id>
  </id_info>
  <brief_title>Effect of High Dose Vitamin D Supplementation on HIV Latency</brief_title>
  <acronym>VIVA</acronym>
  <official_title>Effect of High Dose Vitamin D Supplementation on HIV Latency: A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melbourne Sexual Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Melbourne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV persists despite antiretroviral therapy (ART) and is associated with chronic&#xD;
      inflammation. This inflammation is thought to prevent an effective immune response against&#xD;
      the virus and is mediated at least in part by gut epithelial permeability and microbial&#xD;
      translocation. HIV accumulates preferentially within Th17 cells with time on ART; these&#xD;
      memory CD4+ T cells are highly susceptible to HIV infection and are concentrated within the&#xD;
      gut. Vitamin D promotes gut epithelial integrity in animal models and exerts&#xD;
      anti-inflammatory effects on the human immune system including down-modulation of Th17 cell&#xD;
      frequency. This study will evaluate whether high dose vitamin D is able to reduce immune&#xD;
      activation and Th17 cell frequency, to improve gut barrier integrity and the gut microbiome&#xD;
      and reduce HIV persistence in participants on long-term suppressive ART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major barrier to a cure for HIV infection is the persistence of latently infected CD4+ T&#xD;
      cells on antiretroviral therapy (ART). HIV is concentrated in vivo in Th17 cells in blood and&#xD;
      the gastrointestinal tract. Th17 cells are critical mediators of mucosal immunity against&#xD;
      bacteria and fungi and are rapidly depleted in the gut following HIV acquisition with&#xD;
      subsequent gut epithelial permeability, microbial translocation and ensuing chronic&#xD;
      inflammation which is not completely reversed on ART. Such inflammation may contribute to HIV&#xD;
      persistence by potentiating T cell proliferation and thereby clonal expansion of infected&#xD;
      cells, by exacerbating CD8+ T cell exhaustion and potentially by promoting viral replication&#xD;
      despite ART.&#xD;
&#xD;
      Vitamin D has pleiotropic effects on the immune system including directing na√Øve CD4+ T cells&#xD;
      away from the Th17 phenotype toward an anti-inflammatory regulatory T cell phenotype. It may&#xD;
      also have beneficial effects on dendritic cell and CD8+ T cell immunity. Furthermore, vitamin&#xD;
      D has been shown in animal models to strengthen gut epithelial integrity and in healthy&#xD;
      volunteers to promote a more diverse gut microbiome.&#xD;
&#xD;
      The investigators plan to perform a pilot randomized double-blind placebo-controlled trial of&#xD;
      high dose vitamin D supplementation in HIV-infected participants on suppressive ART and to&#xD;
      determine its effect on immune activation, Th17 cell frequency, gut barrier integrity, the&#xD;
      gut microbiome and HIV persistence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">May 21, 2019</completion_date>
  <primary_completion_date type="Actual">May 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total HIV DNA level</measure>
    <time_frame>weeks 0 and 24</time_frame>
    <description>The difference between the vitamin D and placebo arms in the mean change in frequency of total HIV DNA within CD4+ T cells from week 0 to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in other DNA markers of HIV persistence</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Total HIV DNA, integrated HIV DNA and 2-LTR circles in peripheral blood CD4+ T cells using PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cell-associated HIV RNA</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Cell-associated unspliced and multiply spliced HIV RNA in peripheral blood CD4+ T cells using RT-PCR and Tat/rev Induced Limiting Dilution Assay (TILDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of immune cells</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>T helper and T cytotoxic subsets, monocytes, dendritic cells and natural killer cells using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T cell subset phenotype</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>T cell subset activation and exhaustion marker and chemokine receptor expression using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV-specific immunity</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>HIV-specific CD4+ and CD8+ T cell frequency and polyfunctionality using HIV peptides and flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cell transcriptional profile</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>CD4+ T cell transcriptional profile using RNA Seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>hsCRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut barrier permeability</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Gut barrier permeability using plasma lipopolysaccharide (LPS), soluble CD14 and intestinal fatty acid binding protein (I-FABP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiome diversity</measure>
    <time_frame>Weeks 0, 24, 36</time_frame>
    <description>Gut microbiome diversity using 16S rRNA sequencing and metagenomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma microbiome abundance and diversity</measure>
    <time_frame>Weeks 0, 24, 36</time_frame>
    <description>Plasma microbiome abundance and diversity using deep sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-hydroxyvitamin D levels</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Serum 25-hydroxyvitamin D levels and correlation between level achieved and each of the other endpoints (efficacy analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium levels</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Serum calcium corrected for albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary calcium levels</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Urinary calcium:creatinine ratios and, where these are abnormal, 24 hour urinary calcium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Weeks 0, 12, 24, 36</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study protocol adherence</measure>
    <time_frame>Weeks 0 to 24</time_frame>
    <description>Adherence to study drug and 1g daily dietary calcium intake as measured by pill count and participant report</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Vitamin D3, 10000 Intl Units Oral Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oleic acid capsule by mouth, daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3, 10000 Intl Units Oral Capsule</intervention_name>
    <description>Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.&#xD;
Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.&#xD;
Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.&#xD;
Rectal swabs will be taken at 0, 24 and 36 weeks.&#xD;
All participants will continue antiretroviral therapy throughout the study.</description>
    <arm_group_label>Vitamin D3, 10000 Intl Units Oral Capsule</arm_group_label>
    <other_name>Treatment Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.&#xD;
Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.&#xD;
Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.&#xD;
Rectal swabs will be taken at 0, 24 and 36 weeks.&#xD;
All participants will continue antiretroviral therapy throughout the study.</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Receiving combination antiretroviral therapy continuously for at least 3 years&#xD;
&#xD;
          -  Viral load suppressed below 40 copies/mL, or below assay limit of quantification where&#xD;
             limit of quantification is above 40 copies/mL, for at least 3 years (excluding single&#xD;
             episodes of HIV viral load 40-500 copies/mL where subsequent viral load was below 40&#xD;
             copies/mL or below assay limit of quantification where limit of quantification is&#xD;
             above 40 copies/mL)&#xD;
&#xD;
          -  Viral load &lt; 40 copies/ml at screening&#xD;
&#xD;
          -  Screening 25-hydroxyvitamin D level within 12 months prior to recruitment between 50nM&#xD;
             and 125nM&#xD;
&#xD;
          -  Agreement not to take any vitamin D containing compounds other than study drug between&#xD;
             screening and conclusion of the study&#xD;
&#xD;
          -  Agreement not to have vitamin D level checked by a treating doctor during the study&#xD;
             unless medically required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any planned change to ART regimen within next 12 months (other than switching&#xD;
             tenofovir disoproxil fumarate to tenofovir alafenamide)&#xD;
&#xD;
          -  Known current acute or chronic hepatitis B, known current acute or chronic hepatitis C&#xD;
             or positive HBsAg or HCV PCR in blood at screening&#xD;
&#xD;
          -  Completion of curative treatment for HCV within 6 months prior to screening&#xD;
&#xD;
          -  HIV-2 infection&#xD;
&#xD;
          -  Any vitamin D supplementation from 6 months prior to the screening 25(OH) vitamin D&#xD;
             test until study commencement (including multivitamins containing vitamin D and cod&#xD;
             liver oil)&#xD;
&#xD;
          -  Any medical indication for vitamin D supplementation, eg osteoporosis, renal&#xD;
             impairment (estimated glomerular filtration rate &lt; 60ml/minute), liver cirrhosis&#xD;
&#xD;
          -  Chronic diarrhoea or fat malabsorption&#xD;
&#xD;
          -  Body mass index (BMI &gt;= 35)&#xD;
&#xD;
          -  Current hypercalcaemia (corrected calcium greater than 2.60mM), current primary&#xD;
             hyperparathyroidism or any history of nephrolithiasis&#xD;
&#xD;
          -  Current hyperthyroidism&#xD;
&#xD;
          -  History of sarcoidosis or active tuberculosis&#xD;
&#xD;
          -  Grade 3 or 4 abnormalities in screening pathology laboratory tests not already&#xD;
             excluded by the above criteria at the discretion of the Principal Investigator&#xD;
&#xD;
          -  Hypersensitivity to vitamin D preparations&#xD;
&#xD;
          -  Concurrent medication with adverse interactions with vitamin D (eg oral&#xD;
             glucocorticoids, phenytoin, carbamazepine, barbiturates, rifampicin, rifabutin, St&#xD;
             John's wort, thiazide diuretics, digoxin, ketoconazole, itraconazole, nefazodone,&#xD;
             isoniazid, cholestyramine, aluminium hydroxide, aripiprazole, danazol, orlistat,&#xD;
             perhexiline or sucralfate use) or possible such use within next 12 months&#xD;
&#xD;
          -  Current interferon, immune checkpoint blocker, histone deacetylase inhibitor, oral&#xD;
             vitamin A or other oral vitamin A analogue (eg acitretin, isotretinoin or tretinoin,&#xD;
             also known as all-trans retinoic acid or ATRA) usage or possible use within next 12&#xD;
             months&#xD;
&#xD;
          -  Current participation in another interventional HIV cure study&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Participants of child-bearing potential unwilling to use at least one form of&#xD;
             effective contraception (with failure rate &lt;1%, eg hormonal contraception,&#xD;
             intrauterine device, abstinence, tubal ligation or partner with vasectomy) from at&#xD;
             least 2 weeks prior to study commencement until at least 4 weeks after discontinuation&#xD;
             of all study medication&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Inability to speak English&#xD;
&#xD;
          -  Medicare ineligibility&#xD;
&#xD;
          -  Major medical or psychiatric illness or substance misuse that could in the opinion of&#xD;
             the investigator impair adherence to the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Lewin, FRACP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Peter Doherty Institute for Infection and Immunity, University of Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Peter Doherty Institute for Infection and Immunity</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital - Department of Infectious Diseases</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Sexual Health Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Melbourne</investigator_affiliation>
    <investigator_full_name>Sharon Lewin</investigator_full_name>
    <investigator_title>Director, The Peter Doherty Institute for Infection and Immunity</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Virus latency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

